Natera (NTRA) PEG Ratio: History & Chart

Natera, Inc.(NTRA)

Medical - Diagnostics & Research · Austin, TX

$410.35+1.88 (+0.46%)

Delayed quote: Oct 2, 2026, 4:00 PM EDT

About Natera, Inc.

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Austin, TX

6,138 employees

www.natera.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Steven Leonard Chapman

View full financials

NAME	MARKET CAP	PEG RATIO	TTM	3Y	5Y
Natera, Inc. (NTRA)	$58.77B	N/A	N/A	N/A	N/A
Cencora, Inc. (COR)vs ›	$60.13B	N/A	2.64	4.42	4.72
Boston Scientific Corporation (BSX)vs ›	$63.32B	0.58	1.40	2.06	2.53
Cardinal Health, Inc. (CAH)vs ›	$53.47B	1.12	1.14	8.52	8.64
Edwards Lifesciences Corporation (EW)vs ›	$49.03B	6.91	4.34	2.32	2.28
Becton, Dickinson and Company (BDX)vs ›	$48.72B	3.22	2.29	13.39	10.32
Agilent Technologies, Inc. (A)vs ›	$47.38B	2.24	2.82	2.72	2.39
Humana Inc. (HUM)vs ›	$46.63B	N/A	2.10	2.03	1.52
Cigna Corporation (CI)vs ›	$71.48B	N/A	2.49	1.40	1.17
Teva Pharmaceutical Industries Limited (TEVA)vs ›	$46.04B	N/A	2.28	1.82	1.47

NAME

MARKET CAP

PEG RATIO

TTM

Natera, Inc. (NTRA)

$58.77B

N/A

Cencora, Inc. (COR)vs ›

$60.13B

N/A

2.64

4.42

4.72

Boston Scientific Corporation (BSX)vs ›

$63.32B

0.58

1.40

2.06

2.53

Cardinal Health, Inc. (CAH)vs ›

$53.47B

1.12

1.14

8.52

8.64

Edwards Lifesciences Corporation (EW)vs ›

$49.03B

6.91

4.34

2.32

2.28

Becton, Dickinson and Company (BDX)vs ›

$48.72B

3.22

2.29

13.39

10.32

Agilent Technologies, Inc. (A)vs ›

$47.38B

2.24

2.82

2.72

2.39

Humana Inc. (HUM)vs ›

$46.63B

N/A

2.10

2.03

1.52

Cigna Corporation (CI)vs ›

$71.48B

N/A

2.49

1.40

1.17

Teva Pharmaceutical Industries Limited (TEVA)vs ›

$46.04B

N/A

2.28

1.82

1.47

PEG Ratio Formula & Definition

PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)

The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.

PEG Ratio: N/A

NTRA PEG Ratio Metrics

NTRA Competitors' PEG Ratio

Growth-Adjusted Valuation

PEG Ratio Formula & Definition

Related Metrics